NCT02128581View on ClinicalTrials.gov

A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

July 31, 2019

Conditions
ObesityDiabetesRoux-en-Y Gastric Bypass
Interventions
DRUG

Exendin-9,39

use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion

OTHER

Saline

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

lead

Mayo Clinic

OTHER

NCT02128581 - A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake | Biotech Hunter | Biotech Hunter